PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 11883645

Peptide acylation by poly(alpha-hydroxy esters).

Andrea Lucke·Josef Kiermaier·Achim Göpferich
View original source ↗Export metadata ↓

Abstract

PURPOSE: Poly(lactic acid) (PLA) and poly(lactic-co-glycolic acid) (PLGA) microspheres were investigated concerning the possible acylation of incorporated peptides. METHODS: Atrial natriuretic peptide (ANP) and salmon calcitonin (sCT) were encapsulated into PLA and PLGA microspheres. Peptide integrity was monitored by HPLC-MS analysis during microsphere degradation for four weeks. sCT fragmentation with endoproteinase Glu-C was used for identifying modified amino acids. Peptide stability in lactic acid solutions was investigated to elucidate possible mechanisms for preventing peptide acylation. RESULTS: Both peptides were acylated by lactic and glycolic acid units inside degrading microspheres in a time-dependent manner. After 21 days, 60% ANP and 7% sCT inside PLA microspheres were acylated. Fragmentation of sCT with endoproteinase Glu-C revealed that besides the N-terminal amine group, lysine, tyrosine or serine are further possible targets to acylation. Stability studies of the peptides in lactic acid solutions suggest that oligomers are the major acylation source and that lower oligomer concentration and higher pH substantially decreased the reaction velocity. CONCLUSIONS: The use of PLA and PLGA for drug delivery needs substantially more circumspection. As, according to FDA standards. the potential hazards of peptide acylation products need to be assessed, our findings may have significant implications for products already on the market. Techniques to minimize the acylation reaction are suggested.

Explore related subjects

AcylationAmino Acid SequenceAtrial Natriuretic FactorCalcitoninChromatography, High Pressure LiquidDrug CompoundingDrug Delivery SystemsDrug StabilityEstersLactic AcidMass SpectrometryMicrospheresMolecular Sequence DataMolecular WeightPeptidesPolyestersPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerPolymersJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Andrea Lucke, Josef Kiermaier, Achim Göpferich. 2002. Peptide acylation by poly(alpha-hydroxy esters).. https://doi.org/10.1023/a%3A1014272816454

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Phospholipase activity on N-acyl phosphatidylethanolamines is critically dependent on the N-acyl chain length.

We have recently shown that an endogenous phospholipase A2 from bovine erythrocytes does not hydrolyse NAPEs (N-acyl L-alpha-phosphatidylethanolamines), which accumulate remarkably in this system [Florin-Christensen, Suarez, Florin-Christensen, Wainszelbaum, Brown, McElwain and Palmer (2001) Proc. Natl. Acad. Sci. U.S.A. 98, 7736-7741]. Here we investigate the causes underlying this resistance. N-acylation of PE (L-alpha-phosphatidylethanolamine) results in alteration of charge, head-group volume and conformation, the last two features depending on the N-acyl chain length. To evaluate each effect separately, we synthesized NAPEs with selected N-acyl chain length. We found that phospholipase A2 has considerable activity against N-acetyl PE, but is poorly active against N-butanoyl PE and only marginally active against N-hexanoyl PE, whereas the activity is completely lost when N-hexadecanoyl PE is presented as a substrate. On the other hand, N-hexanoyl PE does not inhibit phospholipase A2 activity, suggesting that this substrate fails to enter the hydrophobic channel. Phospholipase C presents a similar, but less sharp pattern. Molecular dynamics simulations of the polar head group of selected NAPEs reveal a substantially increased conformational variability as the N-acyl chain grows. This larger conformational space represents an increased impairment limiting the access of these molecules to the active site. Our data indicate that, whereas a change in charge contributes to diminished activity, the most relevant effects come from steric hindrance related to the growth of the N-acyl chain.

Acylation↗
PubMed2003

Decreased mitochondrial tRNALys steady-state levels and aminoacylation are associated with the pathogenic G8313A mitochondrial DNA mutation.

Mutations in human mitochondrial tRNA genes cause a number of multisystemic disorders. A G-to-A transition at position 8313 (G8313A) transition in the mitochondrial tRNALys gene has been associated with a childhood syndrome characterized by gastrointestinal-system involvement and encephaloneuropathy. We have used transmitochondrial cybrid clones harbouring patient-derived mitochondrial DNA with the G8313A mutation for the study of the molecular pathogenesis. Our results showed that mutant mitochondrial cybrids respired poorly, and had severely defective mitochondrial protein synthesis and respiratory-chain-enzyme activity. Mutant cybrids also showed a marked decrease in tRNALys steady-state levels and aminoacylation, suggesting that these molecular abnormalities may underlie the pathogenesis of the mitochondrial G8313A mutation.

Acylation↗
PubMed2003

HPLC-DAD-MS/MS ESI characterization of unusual highly glycosylated acylated flavonoids from cauliflower (Brassica oleracea L. var. botrytis) agroindustrial byproducts.

In a recent program to investigate the possible use of vegetable handling and commercialization wastes and residues as a source of potentially bioactive extracts, we have studied cauliflower byproducts. A total of twenty-eight compounds were characterized by HPLC-DAD-MS, of these, twenty-two are produced naturally by the plant. The main compounds found were kaempferol 3-diglucoside-7-glucoside and its combinations with different hydroxycinnamic acids. Moreover, some flavonoids with an unusual high grade of glycosylation have been isolated and tentatively identified for the first time. To our knowledge, the characterization of flavonoids with more than four sugars has not been previously reported. The new products isolated were tentatively identified as kaempferol 3-diglucoside-7-diglucoside, kaempferol 3-triglucoside-7-diglucoside, kaempferol 3-feruloyldiglucoside-7-diglucoside, kaempferol 3-sinapoyltriglucoside-7-glucoside, kaempferol 3-disinapoyltriglucoside-7-glucoside, kaempferol 3-sinapoyltriglucoside-7-diglucoside and kaempferol 3-disinapoyltriglucoside-7-diglucoside.

Acylation↗